Pharmacogenomics of infliximab therapy, impact of TNFRSF1A and TNFRSF1B gene polymorphisms

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00072502" target="_blank" >RIV/00216224:14110/13:00072502 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/13:E0103650
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Pharmacogenomics of infliximab therapy, impact of TNFRSF1A and TNFRSF1B gene polymorphisms
Original language description
Introduction. Anti-TNF alpha monoclonal antibodies present an effective way of treating Crohn's disease ( CD). Despite their high benefits, there is about 30% rate of a primary non-response. The main target of infliximab is the soluble form of TNF alpha,which blocks its pro-inflammatory activity and the induction of apoptosis via the TNF alpha membrane form. The activity of TNF alpha and balance between its pro-inflammatory and pro-apoptotic effect is mediated by the interaction with its receptors (TNFR). Mechanisms of signaling via TNF alpha-TNFR interaction has been recently intensively studied from a perspective of selecting appropriate candidates for the infliximab treatment. Aim. The aim of this study was to evaluate whether polymorphisms in TNFRSF1A and TNFRSF1B genes influence the efficacy of the infliximab therapy. Methods. A total of 116 Caucasian CD patients treated with infliximab were genotyped.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)